Literature DB >> 32476272

The XVth Banff Conference on Allograft Pathology the Banff Workshop Heart Report: Improving the diagnostic yield from endomyocardial biopsies and Quilty effect revisited.

Jean-Paul Duong Van Huyen1,2, Marny Fedrigo3, Gregory A Fishbein4, Ornella Leone5, Desley Neil6, Charles Marboe7, Eliot Peyster8, Jan von der Thüsen9, Alexandre Loupy1,10, Michael Mengel11, Monica P Revelo12, Benjamin Adam11, Patrick Bruneval1, Annalisa Angelini3, Dylan V Miller13, Gerald J Berry14.   

Abstract

The XVth Banff Conference on Allograft Pathology meeting was held on September 23-27, 2019, in Pittsburgh, Pennsylvania, USA. During this meeting, two main topics in cardiac transplant pathology were addressed: (a) Improvement of endomyocardial biopsy (EMB) accuracy for the diagnosis of rejection and other significant injury patterns, and (b) the orphaned lesion known as Quilty effect or nodular endocardial infiltrates. Molecular technologies have evolved in recent years, deciphering pathophysiology of cardiac rejection. Diagnostically, it is time to integrate the histopathology of EMBs and molecular data. The goal is to incorporate molecular pathology, performed on the same paraffin block as a companion test for histopathology, to yield more accurate and objective EMB interpretation. Application of digital image analysis from hematoxylin and eosin (H&E) stain to multiplex labeling is another means of extracting additional information from EMBs. New concepts have emerged exploring the multifaceted significance of myocardial injury, minimal rejection patterns supported by molecular profiles, and lesions of arteriolitis/vasculitis in the setting of T cell-mediated rejection (TCMR) and antibody-mediated rejection (AMR). The orphaned lesion known as Quilty effect or nodular endocardial infiltrates. A state-of-the-art session with historical aspects and current dilemmas was reviewed, and possible pathogenesis proposed, based on advances in immunology to explain conflicting data. The Quilty effect will be the subject of a multicenter project to explore whether it functions as a tertiary lymphoid organ.
© 2020 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  classification systems; clinical research/practice; heart (allograft) function/dysfunction; heart transplantation/cardiology; pathology/histopathology; rejection

Mesh:

Year:  2020        PMID: 32476272     DOI: 10.1111/ajt.16083

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  4 in total

1.  Computational Analysis of Routine Biopsies Improves Diagnosis and Prediction of Cardiac Allograft Vasculopathy.

Authors:  Eliot G Peyster; Andrew Janowczyk; Abigail Swamidoss; Samhith Kethireddy; Michael D Feldman; Kenneth B Margulies
Journal:  Circulation       Date:  2022-04-11       Impact factor: 39.918

2.  An automated computational image analysis pipeline for histological grading of cardiac allograft rejection.

Authors:  Eliot G Peyster; Sara Arabyarmohammadi; Andrew Janowczyk; Sepideh Azarianpour-Esfahani; Miroslav Sekulic; Clarissa Cassol; Luke Blower; Anil Parwani; Priti Lal; Michael D Feldman; Kenneth B Margulies; Anant Madabhushi
Journal:  Eur Heart J       Date:  2021-06-21       Impact factor: 35.855

Review 3.  A Review of Biomarkers of Cardiac Allograft Rejection: Toward an Integrated Diagnosis of Rejection.

Authors:  Guillaume Coutance; Eva Desiré; Jean-Paul Duong Van Huyen
Journal:  Biomolecules       Date:  2022-08-18

4.  Prevention of vascular-allograft rejection by protecting the endothelial glycocalyx with immunosuppressive polymers.

Authors:  Erika M J Siren; Haiming D Luo; Franklin Tam; Ashani Montgomery; Winnie Enns; Haisle Moon; Lyann Sim; Kevin Rey; Qiunong Guan; Jiao-Jing Wang; Christine M Wardell; Mahdis Monajemi; Majid Mojibian; Megan K Levings; Zheng J Zhang; Caigan Du; Stephen G Withers; Jonathan C Choy; Jayachandran N Kizhakkedathu
Journal:  Nat Biomed Eng       Date:  2021-08-09       Impact factor: 25.671

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.